Biosimilars: a cure to the U.S. health care cost conundrum?
Blood Rev
; 28(6): 263-8, 2014 Nov.
Article
in En
| MEDLINE
| ID: mdl-25260225
ABSTRACT
As the cost of healthcare continues to rise and patents on biologics near expiration, biosimilars are gaining visibility as a mechanism for cost reduction. Yet, the introduction of biosimilars into the U.S. market will be complex, due to the related complexity of production, research requirements, and regulatory uncertainty. The purpose of this paper is to frame the relevant issues in order to provide context for stakeholders. It is particularly crucial that clinicians understand the scientific, regulatory, legislative and economic considerations involved in order to ensure that the path to approval is consistent with their needs and that appropriate utilization occurs, once approved.
Key words
Full text:
1
Database:
MEDLINE
Main subject:
Health Care Costs
/
Biosimilar Pharmaceuticals
Type of study:
Health_economic_evaluation
Limits:
Humans
Country/Region as subject:
America do norte
Language:
En
Year:
2014
Type:
Article